Document Type

Article

Publication Date

1-1-2019

Publication Title

RMD Open

Keywords

DMARDs (biologic); disease activity; psoriatic arthritis

Abstract

Objective: This

Methods: In ASTRAEA, patients with active PsA were randomised (1:1) to receive blinded weekly SC abatacept 125 mg or placebo for 24 weeks. Treatment response at week 24 was assessed by the proportions of patients achieving American College of Rheumatology 20% improvement response, Disease Activity Score in 28 joints (DAS28 (C reactive protein (CRP))) ≤3.6 and

Results: Of 212/213 and 210/211 patients with baseline BMI data in the abatacept and placebo groups, respectively, 15% and 19% were underweight/normal, 36% and 27% were overweight, and 49% and 54% were obese. After adjusting for baseline characteristics, there were no significant differences for any outcome measure at week 24 with abatacept in the overweight or obese versus underweight/normal subgroup. In the placebo group, patients in the obese versus underweight/normal subgroup were significantly less likely to achieve DAS28 (CRP)

Conclusion: BMI does not impact clinical or radiographic response to SC abatacept in patients with PsA.

Trial registration number: NCT01860976.

Clinical Institute

Orthopedics & Sports Medicine

Department

Rheumatology

Department

Orthopedics

Download

PSJH Full Text

COinS